Levocabastine
- Generic Name
- Levocabastine
- Brand Names
- Livostin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29FN2O2
- CAS Number
- 79516-68-0
- Unique Ingredient Identifier
- H68BP06S81
- Background
Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
- Indication
As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray for allergic rhinitis.
- Associated Conditions
- Allergic Conjunctivitis (AC), Allergic Rhinitis (AR)
- Associated Therapies
- -
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 459
- Registration Number
- NCT02498509
- Locations
- 🇰🇷
Samsung Medical Center, Irwon-dong, Gangnam-gu, Seoul, Korea, Republic of
A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 71
- Registration Number
- NCT01957202
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- Drug: LevocabastineDrug: Placebo
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT01949051
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath